CpG-oligodeoxynucleotide rejection of a neuroblastoma in A/J mice does not induce a paraneoplastic disease.
Oligodeoxynucleotides containing CpG motifs (CpG-ODN) are powerful immunostimulating agents that are currently entering clinical trials in various human diseases. Concerns exist about potential auto-immune diseases triggered by such treatment. We thus investigated whether tumor rejection induced by CpG-ODN treatment could lead to a harmful auto-immune reaction against the nervous system (neurological paraneoplastic disease) at the time of acute tumor rejection, or in long-term surviving animals. Mice bearing established neuroblastomas were treated with intra-tumoral injections of CpG-ODN, resulting in tumor inhibition and tumor rejection in one-third of the animals. Immunocytochemistry and Western blot studies revealed no specific anti-neuronal antibodies. None of the animals developed neurological disabilities and histological studies of the nervous system were normal. CpG-ODN can therefore trigger neuroblastoma rejection without inducing neurological paraneoplastic disease.
Fédération de Neurologie Mazarin and Institut National de la Santé et de la Recherche Médicale (INSERM) U-495, Hôpital de la Salpêtrière, 75013, Paris, France.
Gregor
G
Auf
Lin
L
Chen
Paul
P
Fornès
Christelle
C
Le Clanche
Jean Yves
JY
Delattre
Antoine F
AF
Carpentier
D000276:Adjuvants, Immunologic / Q000009:adverse effects*; D000818:Animals; D015551:Autoimmunity; D015153:Blotting, Western; D007150:Immunohistochemistry; D051379:Mice; D009447:Neuroblastoma / Q000188:drug therapy*; D009838:Oligodeoxyribonucleotides / Q000009:adverse effects*; D020364:Paraneoplastic Polyneuropathy / Q000139:chemically induced* / Q000276:immunology*; D013997:Time Factors
D000276:Adjuvants, Immunologic; C408982:CPG-oligonucleotide; D009838:Oligodeoxyribonucleotides